What were the biggest #SCLC highlights from #WCLC2026? Watch Giannis Mountzios share his perspective on the MAVERICK trial, novel antibody-drug conjugates, and evolving treatment strategies that are reshaping the care landscape

https://ow.ly/likl50ZTplF

First-line trastuzumab deruxtecan (T-DXd) prolongs PFS, but not overall survival, in metastatic, HER2-mutant #NSCLC

Julia Rotow, MD, from @danafarber.bsky.social presented research from the DESTINY-Lung 04 trial this week at #WCLC2026 @iaslc.bsky.social

Full article: https://bit.ly/4gY7oK6

Join our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026!
Register: events.teams.microsoft.com/event/681070...

#WCLC2026 #ESMO2026 #LungCancer #Oncology

DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌

DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão

DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone

DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs

DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2

DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2

🌏 That’s a wrap on #WCLC2026!

Congratulations to Dr Stephen Wong on a fantastic poster, highlighting methylation differences between immunotherapy responders and non-responders and potential biomarkers of treatment response and resistance in lung cancer. 👏

#LungCancer #Biobank

Phase 3 REZILIENT3 trial results presented at #WCLC2026:

Adding the TKI zipalertinib to 1L chemotherapy improves outcomes in EGFR ex20ins #NSCLC:
• Median PFS: 14.5 vs 8.5 mos
• ORR: 65.0% vs 40.3%
• Median DOR: 14.2 vs 9.9 mos

Full Article: https://bit.ly/46pC3Kk

Ph3 DESTINY-Lung04: #Enhertu erzielt 14,3 Mo. mPFS vs. 8,3 Mo. mit #Pembrolizumab + Chemo bei 1L HER2-mutiertem #NSCLC (37% geringeres Risiko Progress/Tod).
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26

DESTINY-Lung04 (Ph3) : #Enhertu atteint 14,3 m de SSP vs 8,3 m sous #pembrolizumab + chimio en 1L dans le #CPNPC muté HER2 (-37% risque décès/progression)
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncologie

#Enhertu alcanzó 14,3 meses de mediana de SLP vs 8,3 meses con #pembrolizumab + quimio en 1L para #CPCNP con mutación HER2
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncología

🤗We were delighted to meet with our editors in person at #WCLC2026!

Thank you for the insightful conversations and continued support in advancing high-quality research in lung cancer✨
#LungCancer #ThoracicOncology #CancersMDPI

Roche, MediLink's ADC boost survival in relapsed SCLC $RHHBY #WCLC2026 firstwordpharma.com/story/7990444

J&J's Rybrevant shows numerical OS gain in difficult-to-treat lung cancer $JNJ #WCLC2026 firstwordpharma.com/story/7989702

BioNTech, OncoC4 tout survival benefit for anti-CTLA-4 in NSCLC $BNTX #WCLC2026 firstwordpharma.com/story/7987350

Enhertu's PFS lung cancer win comes with an OS question mark $AZN $DSNKY #WCLC2026 firstwordpharma.com/story/7990485

New phase 3 ARTEMIS-008 trial results presented at #WCLC2026:

Risvutatug rezetecan (ris-rez) significantly improved median overall survival vs. topotecan in relapsed small cell lung cancer (18.5 vs. 10.3 months). 🫁

Read the full article: https://bit.ly/3URwcuE